Tag Archives | Orphan drugs

Biotech Momentum Eases: September is a Bit Sluggish…Update after FED Meeting-9/20

Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived: ABBV and REGN are leaders over 1%. Mid-cap big mover Alnylam […]

Continue Reading 0

Large Cap Biopharmaceutical Valuations: Q1 2017

May 8, 2017  Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%.  The large cap focused IBB […]

Continue Reading 0

Biotechs Running Again: Rayno Life Science Stocks-See Picks…Earnings Updates

Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for EPS was confirmed at $5.44-5.54. Stock closed up 1.55% today to $66.05. Alexion […]

Continue Reading 0

Biotech Sector Leads Market Early in 2017 Despite Uncertainties…Update

Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at $287.67 breaking the $290 technical level not seen since […]

Continue Reading 0

Biotech Blahs: Out of Favor But Great For Stock Pickers…Update-2

Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the JPMorgan Healthcare Conference next Monday. Despite extremely negative sentiment on the sector, demand for […]

Continue Reading 0

Market Reversal in Biotech But Healthcare Stocks Are Still Muddled

Market Reversal in Biotech Offers Bullish Set-Up After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal. The macro environment got support from economic data as well with upward Q3 GDP revisions to 3.2% and higher consumer confidence data. The economy now has the […]

Continue Reading 0

Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

Trump Election Win Drives Huge Biotech Rally NASDAQ up over 1% to 5248 The Trump biotech rally began at today’s opening up (IBB) 20 points to $280 then held to close  up 8.9% to $285. The XBI soared 10.4% to close at $63.8 near highs of day. The cloud of drug pricing concerns vanished because […]

Continue Reading 0

Biotech Meltdown: Financial Metrics Offer Few Clues For What is Next

Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have been taken down because price increases are not likely for 2017 . Another […]

Continue Reading 0

Biotech Stocks Recovering from Last Week’s Free Fall: XBI…Update-2

Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft down 49% for the week. The IBB also took a […]

Continue Reading 0

Biotech Blahs: Unable To Hold Gains After ASCO Run-Up…Update-1

Monday June 20… Update 4:30p EDT…BRexit relief rally Biotech stocks pretty much tracked the NASDAQ rally today slowly selling off as the day wore on. The more volatile XBI was still up 1.56% for the day beating the sluggish IBB up 0.91%. The healthcare sector overall held up about 1%. Energy and materials led up […]

Continue Reading 0